USPTO Examiner RAO SAVITHA M - Art Unit 1629

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18949105PARTICULATE COMPOSITIONNovember 2024January 2025Allow200YesNo
18753759PARTICULATE COMPOSITIONJune 2024September 2024Allow300YesNo
18734388METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMAJune 2024December 2024Allow611YesNo
18671935SULFONYLHYDRAZIDE DERIVATIVES AS ANTICANCER AGENTSMay 2024December 2024Allow701YesNo
18655793HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGMay 2024August 2024Allow301YesNo
18625188SESQUITERPENOID DERIVATIVE AND USE THEREOF IN PREPARING BROAD-SPECTRUM ANTIVIRAL DRUGApril 2024October 2024Allow710NoNo
184372295-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024May 2024Allow300NoNo
18409768PYRIMIDO[1'6':1,5]PYRAZOLO[4,3-C][1,7]NAPHTHYRIDINES AS CK2 INHIBITORSJanuary 2024July 2024Allow601YesNo
18391360USE OF L-ERGOTHIONEINE TO AMELIORATE AND PREVENT AGE-RELATED VITREOUS DEGENERATIONDecember 2023August 2024Allow810YesNo
18526535CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFDecember 2023February 2024Allow200YesNo
18385809SUBSTITUTED 1,3,4-OXADIAZOLE DERIVATIVES AS ANTI-TUBERCULAR AGENTSOctober 2023April 2024Allow620NoNo
184947345-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023April 2024Allow621NoNo
18381767CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFOctober 2023April 2024Allow610YesNo
18487887COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERSOctober 2023December 2023Allow200YesNo
18483630COMPOSITIONS AND METHODS FOR PROMOTING GLYCOGEN SYNTHASE ACTIVITY AND AUGMENTING GLYCOGEN STORAGE CAPABILITYOctober 2023August 2024Allow1110YesNo
18466547Methods of Treating Prostate CancerSeptember 2023February 2024Allow510YesNo
18222061COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSJuly 2023November 2023Allow410YesNo
18219903ARSINOTHRICIN AS A MULTI-STAGE ANTIMALARIALJuly 2023December 2023Allow510NoNo
18328397STORAGE STABLE AQUEOUS PARENTERAL SOLUTIONS COMPRISING DICLOFENACJune 2023February 2025Allow2000YesNo
18201938ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOFMay 2023July 2024Allow1421YesNo
18031998Compositions and Methods for the Prevention and Treatment of Hearing LossApril 2023April 2024Abandon1201YesNo
18130597STABLE ORAL SUSPENSIONS OF BACLOFENApril 2023June 2023Allow300YesNo
18126551COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSMarch 2023June 2023Allow300YesNo
18088382PHARMACEUTICAL FORMULATIONS OF TAFAMIDISDecember 2022August 2023Allow811NoNo
18087625STABLE ORAL SUSPENSIONS OF BACLOFENDecember 2022March 2023Allow300YesNo
18073632TANNIN-CONTAINING GASTROINTESTINAL FORMULATIONS AND METHODS OF USEDecember 2022November 2024Allow2300YesNo
17992290Compositions And Methods For Inhibiting Type 1 Collagen ProductionNovember 2022January 2025Allow2601YesNo
17989462Methods of Treating Prostate CancerNovember 2022July 2023Allow810NoNo
17989420Methods of Treating Prostate CancerNovember 2022July 2023Allow810NoNo
17989329Methods of Treating Prostate CancerNovember 2022July 2023Allow810NoNo
18049468ANTITOXINS TO BREVETOXINOctober 2022July 2023Allow801YesNo
18046919COMPOSITIONS AND METHODS FOR TREATING HYPERPHAGIA IN PRADER-WILLI SYNDROMEOctober 2022November 2024Allow2500YesNo
17937215METHOD FOR PREVENTING PREGNANCYSeptember 2022September 2023Allow1230NoNo
17934244PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMSeptember 2022December 2022Allow300YesNo
17948882STABLE ORAL SUSPENSIONS OF BACLOFENSeptember 2022December 2022Allow300YesNo
17944506COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERSSeptember 2022December 2024Allow2701YesNo
17941640PHENYLEPHRINE HYDROCHLORIDE READY-TO-USE SOLUTIONSeptember 2022December 2024Allow2710YesNo
17903080HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGSeptember 2022January 2024Allow1711NoNo
17901951CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFSeptember 2022September 2023Allow1321YesNo
17822027UROLITHINS AS IMMUNE RESPONSE ENHANCERSAugust 2022June 2024Allow2200NoNo
17893105USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORSAugust 2022March 2025Abandon3010YesNo
17891251ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITORAugust 2022January 2025Abandon2910NoNo
17890659Halogenated Xanthene Composition and Method for Treating Hematologic CancersAugust 2022September 2024Allow2501YesNo
17858827CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFJuly 2022July 2023Allow1230YesNo
17858826CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFJuly 2022November 2023Allow1631YesNo
17851862Method of Treating Diseases of the Visual SystemJune 2022December 2023Allow1720NoNo
17850050COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSJune 2022December 2022Allow610YesNo
17839147COMPOSITION AND METHOD FOR PREVENTING LONG-TERM COVID-19 MORBIDITYJune 2022November 2024Allow2901YesNo
17837666AMINO ACID COMPOSITIONS FOR THE AMELIORATION OF SYMPTOMS OF ENVIRONMENTAL ENTEROPATHYJune 2022July 2024Allow2600YesNo
17825773METHODS TO DECREASE TRIGLYCERIDE SYNTHESIS IN THE LIVERMay 2022November 2024Allow2910NoNo
17749887COMPOSITIONS AND METHODS FOR TREATING DRY EYEMay 2022April 2024Allow2300NoNo
17744369Polyoxometalate Complexes and Pharmaceutical CompositionsMay 2022June 2024Allow2600NoNo
17743201METHODS AND COMPOSITIONS FOR TREATING ECTOPARASITE INFESTATIONSMay 2022February 2023Allow911NoNo
17741993P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHDMay 2022December 2024Abandon3210NoNo
17741427CRYSTALLINE FORMSMay 2022October 2024Allow2910YesNo
17739648THERAPEUTIC USE OF LEVOROTATORY BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELSMay 2022July 2024Allow2702YesNo
17736257USE OF NOREPINEPHRINE OR BETA-ADRENERGIC RECEPTOR INHIBITOR IN PREPARATION OF MEDICAMENT FOR NERVE INJURY REPAIR IN DIABETESMay 2022April 2024Abandon2411NoNo
17734878Threonate Compounds and Methods of Use ThereofMay 2022September 2024Abandon2801NoNo
17732655COMPOSITIONS FOR MANAGEMENT OF POLYCYSTIC OVARY SYNDROMEApril 2022October 2024Allow2910YesNo
17732667PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONSApril 2022May 2024Allow2510YesNo
17720255USE OF A NITROGEN-CONTAINING BISPHOSPHONATE IN COMBINATION WITH A GLUCOCORTICOID IN PREVENTING OR TREATING VIRAL PNEUMONIAApril 2022May 2024Allow2521NoNo
17716708METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECTApril 2022October 2024Allow3010YesNo
17716982COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDSApril 2022February 2024Allow2211YesNo
17714723SYNERGISTIC COMPOSITION FOR POTENTIATING STABILIZED ATPApril 2022September 2024Allow2910NoNo
17657546PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMMarch 2022June 2022Allow300YesNo
17707221BUPROPION AS A MODULATOR OF DRUG ACTIVITYMarch 2022July 2022Allow300YesNo
17692376Repurposing Anti-Androgen Therapy for COVID-19 and ImmunotherapyMarch 2022April 2024Allow2620YesNo
17688222COMPOSITIONS AND METHODS FOR TREATING CHEMOTHERAPY RESISTANT CANCERMarch 2022September 2024Allow3010NoNo
17680817METHODS OF TREATING HYPERTRIGLYCERIDEMIAFebruary 2022July 2024Abandon2810NoNo
17666964COMPOSITIONS OF HYDROXY ACIDS WITH SALICYLIC ACID AND USES THEREFOREFebruary 2022June 2024Allow2821NoNo
17666201MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSFebruary 2022April 2023Allow1430YesNo
17591438STABLE ORAL SUSPENSIONS OF BACLOFENFebruary 2022August 2022Allow610YesNo
17589732NON-INVASIVE METHOD OF TREATING COVID-19 INFECTIONJanuary 2022November 2023Abandon2201NoNo
17582286BIOMARKERS USEFUL IN THE TREATMENT OF SUBJECTS HAVING DISEASES OF THE EYEJanuary 2022May 2024Allow2800YesNo
17577821METHODS OF CONTROLLING MYOCARDIAL BLOOD FLOWJanuary 2022September 2023Abandon2001NoNo
17576485TRPV1 ACTIVATION-MODULATING COMPLEX MIXTURES OF CANNABINOIDS AND/OR TERPENESJanuary 2022November 2024Abandon3410NoNo
17576075TERAMEPROCOL AND NORDIHYDROGUAIARETIC ACID (NDGA) DERIVATIVES AS CORONAVIRUS ANTI-VIRAL AGENTSJanuary 2022August 2023Allow1911YesNo
17573503COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED DISORDERSJanuary 2022January 2024Allow2511YesNo
17560373METHODS OF TREATING MYELOPROLIFERATIVE DISORDERSDecember 2021June 2022Allow510YesNo
17557987TITRATION OF CEBRANOPADOLDecember 2021July 2024Allow3110YesNo
17552967DICARBOXYLIC ACID ESTERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH PHOSPHOLIPASE D TOXINDecember 2021October 2023Allow2211YesNo
17552943DICARBOXYLIC ACID ESTERS FOR INDUCING AN ANALGESIC EFFECTDecember 2021October 2023Allow2211YesNo
17644299EXTERNAL USE COMPOSITION COMPRISING PAEONOL AND PANTHENOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENTSDecember 2021April 2022Allow400YesNo
17644295METHODS FOR TREATING IMMUNODEFICIENCY DISEASEDecember 2021October 2024Abandon3420YesNo
17535103D9-CAFFEINE COMPOSITIONS AND USES THEREOFNovember 2021September 2024Allow3350NoYes
17525394P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHDNovember 2021July 2024Allow3210NoNo
17514390Therapeutic NanomaterialsOctober 2021July 2024Allow3211NoNo
17514481ENALAPRIL FORMULATIONSOctober 2021October 2023Allow2310YesNo
17604124ADRENALINE PHARMACEUTICAL SOLUTION FOR AN INJECTION DEVICEOctober 2021May 2022Allow700NoNo
17501130METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSSOctober 2021October 2023Allow2411NoNo
17602101SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONSOctober 2021August 2024Allow3501YesNo
17495548PHENYLEPHRINE HYDROCHLORIDE READY-TO-USE SOLUTIONOctober 2021June 2022Allow810YesNo
17449412LIQUID FORMULATIONS OF INDACATEROLSeptember 2021September 2023Allow2411NoNo
17488252PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE, FAMOTIDINE AND MELATONINSeptember 2021September 2024Abandon3641NoNo
17484025Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneSeptember 2021July 2024Allow3411NoNo
17482241BUPROPION AS A MODULATOR OF DRUG ACTIVITYSeptember 2021November 2021Allow200YesNo
17479523COMPOSITIONS AND USES THEREOF FOR TREATMENT OF IDIOPATHIC PRETERM BIRTHSeptember 2021September 2023Allow2411NoNo
17478134Use of Bromophenol-pyrazoline Compounds in the Treatment of Porcine Coronavirus DiseasesSeptember 2021April 2023Allow1901YesNo
17475212PREVENTION AND/OR TREATMENT OF CONTRAST-INDUCED ACUTE KIDNEY INJURYSeptember 2021January 2024Allow2810NoNo
17472870COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORSSeptember 2021April 2024Abandon3110NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, SAVITHA M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
4
(50.0%)
Examiner Reversed
4
(50.0%)
Reversal Percentile
69.2%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
37
Allowed After Appeal Filing
10
(27.0%)
Not Allowed After Appeal Filing
27
(73.0%)
Filing Benefit Percentile
36.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 27.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RAO, SAVITHA M - Prosecution Strategy Guide

Executive Summary

Examiner RAO, SAVITHA M works in Art Unit 1629 and has examined 630 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner RAO, SAVITHA M's allowance rate of 62.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RAO, SAVITHA M receive 1.24 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RAO, SAVITHA M is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +49.2% benefit to allowance rate for applications examined by RAO, SAVITHA M. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.6% of applications are subsequently allowed. This success rate is in the 67% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 46.0% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 47.1% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 50% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.